about
Inflammation in HIV-infected patients: impact of HIV, lifestyle, body composition, and demography - a cross sectional cohort studyExercise increases interleukin-10 levels both intraarticularly and peri-synovially in patients with knee osteoarthritis: a randomized controlled trial.Cholesterol-induced protein sorting: an analysis of energetic feasibilityRisk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population.Feasibility and inter-rater reliability of physical performance measures in acutely admitted older medical patients.Death from the Nile crosses the Atlantic: the West Nile Fever story.Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review.Immunosenescence of the CD8(+) T cell compartment is associated with HIV-infection, but only weakly reflects age-related processes of adipose tissue, metabolism, and muscle in antiretroviral therapy-treated HIV-infected patients and controls.Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls.Prediction of Mobility Limitations after Hospitalization in Older Medical Patients by Simple Measures of Physical Performance Obtained at Admission to the Emergency Department.New lidocaine lozenge as topical anesthesia compared to lidocaine viscous oral solution before upper gastrointestinal endoscopy.Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infeFeasibility of progressive sit-to-stand training among older hospitalized patients.Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study.Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study.Serum amyloid P component binds to influenza A virus haemagglutinin and inhibits the virus infection in vitro.Effect of a local anesthetic lozenge in relief of symptoms in burning mouth syndrome.Performance of the TREAT decision support system in an environment with a low prevalence of resistant pathogens.suPAR associates to glucose metabolic aberration during glucose stimulation in HIV-infected patients on HAART.Inflammation and post-operative recovery in patients undergoing total knee arthroplasty-secondary analysis of a randomized controlled trial.[Epstein-Barr virus-associated large B-cell lymphoma in a patient with colitis ulcerosa treated with azathioprine].Different growth hormone sensitivity of target tissues and growth hormone response to glucose in HIV-infected patients with and without lipodystrophy.Low-dose growth hormone therapy reduces inflammation in HIV-infected patients: a randomized placebo-controlled study.T-lymphocyte subset dynamics in well-treated HIV-infected men during a bout of exhausting exercise.Prevalence and overlap of Disease Management Program diseases in older hospitalized patients.Association of markers of bacterial translocation with immune activation in decompensated cirrhosis.Bupivacaine Lozenge Compared with Lidocaine Spray as Topical Pharyngeal Anesthetic before Unsedated Upper Gastrointestinal Endoscopy: A Randomized, Controlled Trial.Erratum to: Association between routine laboratory tests and long-term mortality among acutely admitted older medical patients: a cohort studyLipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in beta-cell function.Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of beta-cells.Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1.Long-term high-physiological-dose growth hormone reduces intra-abdominal fat in HIV-infected patients with a neutral effect on glucose metabolism.Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.Polyacrylamide gel treatment of antiretroviral therapy-induced facial lipoatrophy in HIV patients.The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy.Psychological stress predicts the risk of febrile episodes in cancer patients during chemotherapy.Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance.CRP and suPAR are differently related to anthropometry and subclinical organ damage.Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels.
P50
Q28484274-8566E049-CA09-4184-A034-7A8427DCC01BQ34152911-ABB3CAA9-AA57-4602-93F5-72AAE40D6021Q34180735-46B6BEFF-15A0-418D-BAAB-EC80E31F1A03Q34722262-33E262BC-F7CB-45F4-93DC-DB6C2DE385C4Q35112870-A9FBB909-BD7F-43DA-AEEA-58F3F03B3D85Q35628958-8F22C346-7997-4DB5-8D22-1BB33C0A7922Q35805765-0DAA92E4-89E4-4533-8566-3F6E9347CB65Q35854044-14F57D6A-E62D-4D4E-85CF-8C5C1FBB4491Q35913712-88E02594-7145-4DDB-8A6A-D72A683806D5Q36022091-87A32AFD-0503-4EB8-BF2D-A9920EB17E68Q36160802-D2752EBB-F643-4D81-8649-BC1174CBA573Q36392555-FC61F9F1-1940-4A94-95B3-1206DA9173A8Q36402139-18FFB9C4-F1FA-41A9-87DA-F8F5F95E41ABQ36633905-1ED72498-F4C8-4C94-A400-840AB266CE8EQ37471630-1B6B9363-F23A-41B4-8DB0-D16194B8902DQ38342046-C15492C3-2138-4FC0-ADAF-E9C21EF4D196Q39180671-11283CBB-E20F-471A-BD7E-6BECB804E728Q40017575-07039B87-97B1-4C87-BBFE-569FB5632585Q40115568-B72201CE-D44B-4490-95BD-859BD578ACA4Q40286195-AC7D09F1-A26E-4E1E-A5A0-57311B091773Q40421000-47B02CEC-95CF-45BC-8312-D227E6B44DADQ40500085-FC514B50-55BA-4032-A43A-A735F8C76C16Q40613036-DEE889BD-A582-478F-BF5E-E6B8A4ACDB16Q41070850-CD3343D3-E70E-4F44-9F9B-2062C43EB738Q41636169-EE9468DB-EA1E-457B-A199-9CE9BAF7AB64Q41683800-9F92D60D-6695-4A24-ABB8-D029502AC2CBQ41910526-F8C0B699-BD9D-4C5C-B57E-36A635ED24C1Q42315955-9FEFB895-1C8D-44F7-BFFB-12DE569EEB3CQ42451513-FF46AA77-F6C5-48D0-9513-85C54B05B612Q42461806-34FD2C7B-129B-4564-BEB3-280C033BDEC6Q43033068-8209B419-1E1A-489A-80D2-792FFDD183D6Q43225296-31DEEE98-86C6-4B22-9C27-6A507BB87714Q43470860-9A2F3CB6-BD50-4526-AB03-15B4CA86F9E3Q43491799-E016205D-FDF6-452C-8E29-EC147FBA261BQ43653935-BD8E0681-52E6-4CC8-A5B6-C93DA6493FDCQ43762398-CC83949A-1DF5-447B-9CB6-7D883605145EQ43932436-AEB523B2-7572-4B09-8810-8FA6E6F87BADQ44224684-4CAC5ED2-68BF-48AF-9BD7-AA1DE78FB6D2Q44493529-5D3C4651-60B6-46A1-AA28-07F3144DE3EAQ44522392-D271BFAF-459C-460F-878B-B8321F0C9532
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ove Andersen
@ast
Ove Andersen
@en
Ove Andersen
@es
Ove Andersen
@nl
Ove Andersen
@sl
type
label
Ove Andersen
@ast
Ove Andersen
@en
Ove Andersen
@es
Ove Andersen
@nl
Ove Andersen
@sl
prefLabel
Ove Andersen
@ast
Ove Andersen
@en
Ove Andersen
@es
Ove Andersen
@nl
Ove Andersen
@sl
P106
P21
P31
P496
0000-0002-2274-548X